Description
TirzepatideĀ is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This unique mechanism of action has made it an exciting compound for research into metabolic disorders, particularly type 2 diabetes, obesity, and related metabolic conditions. By simultaneously targeting two key incretin pathways, tirzepatide offers novel potential for improving glycemic control, promoting weight loss, and regulating metabolic health.





Reviews
There are no reviews yet.